Home Apoptosis Bcl-2 modulator Ruxotemitide (LTX 315)

research use only

Ruxotemitide (LTX 315) Bcl-2 modulator

Cat.No.S8199

Ruxotemitide (LTX 315) is the oncolytic peptide that kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization.
Ruxotemitide (LTX 315) Bcl-2 modulator Chemical Structure

Chemical Structure

Molecular Weight: 1439.79

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Chemical Information, Storage & Stability

Molecular Weight 1439.79 Formula

C78H106N18O9

 Storage (From the date of receipt)
CAS No. 1345407-05-7 Download SDF Storage of Stock Solutions

Solubility

In vitro
Batch:

Water : 100 mg/mL

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

In vitro
LTX-315 is highly active against both murine and human melanoma cell lines in vitro. while displaying low EC50 cytotoxic activity against human red blood cells. LTX-315 has been shown to induce the release of ATP and HMGB1 in vitro, both being DAMPs involved in ICD[1].
In vivo
when syngeneic B16 melanomas are treated intralesionally, a majority of the animals (~80%) treated with LTX-315 experience a complete and long-lasting tumor regression. LTX-315 injection induces an extensive hemorrhagic necrosis of the tumor parenchyma and a massive infiltration of CD3+ T cells, indicating that the peptide induces a type of cell death that leads to an increase in the number of tumor-infiltrating lymphocytes (TILs). treatment of a single tumor with LTX-315 generates a systemic anti-tumor immune response that eradicated distant lesions and prevented reoccurrence following tumor rechallenge[1].
References

Applications

Methods Biomarkers Images PMID
Immunofluorescence SMAC BAX S8199-IF1 26378049
Growth inhibition assay Cell viability S8199-viability1 21453492

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03725605 Completed
Soft Tissue Sarcoma
Lytix Biopharma AS|Herlev Hospital
 December 28 2018 Phase 2
NCT01223209 Completed
Carcinoma
Lytix Biopharma AS|Kael-GemVax Co. Ltd.
 August 2010 Phase 1
NCT01058616 Completed
Cancer With Transdermal Accessible Tumour
Lytix Biopharma AS|Oslo University Hospital|Karolinska University Hospital
 January 2010 Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Signaling Pathway Map